Limited value of CA 19-9 in predicting early treatment failure in patients with advanced pancreatic cancer

Oncology

Volumn 77, Issue 2, 2008, Pages 140-146

  Vormittag, Laurenz ^a   Gleiss, Andreas ^a   Scheithauer, Werner ^a   Lang, Fritz ^b   Laengle, Friedrich ^c   Kornek, Gabriela V ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b City Hospital Neunkirchen   (Germany)

^c Wr Neustadt General Hospital   (Austria)

Author keywords

CA 19 9; Pancreatic cancer; Prognosis; Treatment outcome

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CAPECITABINE; CISPLATIN; CYTOSTATIC AGENT; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEMCITABINE; OXALIPLATIN; TIPIFARNIB;

ADULT; ADVANCED CANCER; AGED; CANCER GROWTH; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; KINETICS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PALLIATIVE THERAPY; PANCREAS CANCER; POPULATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 67651007764     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000229754     Document Type: Review

References (23)

1. Ishii H, Furuse J, Nakachi K, Suzuki E, Yo-shino M: Primary tumor of pancreatic cancer as a measurable target lesion in chemotherapy trials. Jpn J Clin Oncol 2005; 35: 601-606.
2. Aoki K, Okada S, Moriyama N, Ishii H, Nose H, Yoshimori M, Kosuge T, Ozaki H, Wakao F, Takayasu K, Mukai K: Accuracy of computed tomography in determining pancreatic cancer tumor size. Jpn J Clin Oncol 1994; 24: 85-87.
3. Riedinger JM, Wafflart J, Ricolleau G, Eche N, Larbre H, Basuyau JP, Dalifard I, Hacene K, Pichon MF: CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multi-centric study. Ann Oncol 2006; 17: 1234-1238.
4. Montgomery RC, Hoffman JP, Riley LB, Ro-gatko A, Ridge JA, Eisenberg BL: Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarci-noma of the pancreas. Ann Surg Oncol 1997:551-556.
5. Sperti C, Pasquali C, Catalini S, Cappellazzo F, Bonadimani B, Behboo R, Pedrazzoli S: CA 19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol 1993; 52: 137-141.
6. Safi F, Schlosser W, Falkenreck S, Beger HG: Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998; 45: 253-259.
7. Tian F, Appert HE, Myles J, Howard JM: Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg 1992; 215: 350-355.
8. Ishii H, Okada S, Sato T, Wakasugi H, Saisho H, Furuse J, Ishikawa O, Matsuno S, Yokoya-ma S: CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 1997; 44: 279-283.
9. Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, Adsay V, Weaver D, Shields AF: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001; 92: 569-577.
10. Stemmler J, Stieber P, Szymala AM, Schal-horn A, Schermuly MM, Wilkowski R, Helmberger T, Lamerz R, Stoffregen C, Nie-bler K, Garbrecht M, Heinemann V: Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or meta-static pancreatic cancer treated with gem-citabine and cisplatin? Onkologie 2003; 26: 462-467.
11. Ziske C, Schlie C, Gorschluter M, Glas-macher A, Mey U, Strehl J, Sauerbruch T, Schmidt-Wolf IG: Prognostic value of CA 19-9 levels in patients with inoperable adenocar-cinoma of the pancreas treated with gem-citabine. Br J Cancer 2003; 89: 1413-1417.
12. Halm U, Schumann T, Schiefke I, Witzig-mann H, Mossner J, Keim V: Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000; 82: 1013-1016.
13. Olbert PJ, Hegele A, Kraeuter P, Heidenreich A, Hofmann R, Schrader AJ: Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs 2006; 17: 993-996.
14. Kiang DT, Greenberg LJ, Kennedy BJ: Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990; 65: 193-199.
15. Sorbye H, Dahl O: Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol 2004; 43: 495-498.
16. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-5327.
17. Ulrich-Pur H, Raderer M, Verena Kornek G, Schull B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Scheit-hauer W: Irinotecan plus raltitrexed vs. ralti-trexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocar-cinoma. Br J Cancer 2003; 88: 1180-1184.
18. Heinze G, Schemper M: Comparing the importance of prognostic factors in Cox and logistic regression using SAS. Comput Methods Programs Biomed 2003; 71: 155-163.
19. Gogas H, Lofts FJ, Evans TR, Daryanani S, Mansi JL: Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adeno-carcinoma of the pancreas? Br J Cancer 1998; 77: 325-328.
20. Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 20: 1182-1191.
21. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA: Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gem-citabine for advanced pancreatic cancer. Br J Cancer 2005; 93: 195-199.
22. Nakai Y, Kawabe T, Isayama H, Sasaki T, Ya-gioka H, Yashima Y, Kogure H, Arizumi T, Togawa O, Ito Y, Matsubara S, Hirano K, Sa-sahira N, Tsujino T, Tada M, Omata M: CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer. Oncology 2008; 75: 120-126.
23. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W, Herrmann R: CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer in a randomised controlled trial. Lancet On-col 2008; 9: 132-138.